BioNTech expects to start shipping two vaccines suitable for the Omicron variant of the coronavirus as early as October, which will help boost demand in the fourth quarter, the German drugmaker said on Monday, which also published its sales forecast for Vaccines for the year reiterated .
The request for vaccinationsof which more than 3.6 billion doses have been shipped worldwide is declining as most people in western countries have already received it three or four cans.
Covid: Why don’t some people get the virus?
campaigns of memory However, the use of cans specifically targeting the Omicron variant should boost demand in the fall. Pending regulatory approval, BioNTech said its two custom-made vaccines would be available in time for campaigns.
Covid: What do we know about BA.4.6, the new Omicron subvariant already dominant in some US states?
Both revenue and net income for the second quarter fell about 40% from the year-ago period to €3.2 billion and €1.672 billion, respectively.
BioNTech reiterated its sales forecast for vaccines in 2022, ie 13 to 17 billion euros compared to 19 billion the previous year. his partner Pfizer forecasts $32 billion in vaccine sales for the year COVID-19.
“With our strong year-to-date performance, we believe we are on track to meet our previous financial guidance for the current fiscal year.”said Jens Holstein, chief financial officer of BioNTech.
“With our strong year-to-date performance, we believe we are on track to meet our previous financial guidance for the current fiscal year,” said Jens Holstein, CFO of BioNTech.
BioNTech and Pfizer submitted one of the matched vaccines targeting subvariant BA.1 to the European Medicines Agency last month, with delivery pending.
The other, targeting subvariants BA.4 and BA.5 as recommended by the US Food and Drug Administration, will begin clinical trials this month, with first doses also expected to ship as soon as possible.